Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says
Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says Maia Anderson | Becker’s Hospital Review “An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S....
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year Alex Brill | Washington, DC Today, Matrix Global Advisors (MGA) released a new report, “The Cost of Brand Drug Product Hopping,” commissioned by the Coalition for...- Don’t Let Pandemic Fatigue Inhibit Pandemic Preparedness
- Macroeconomics of the Child Tax Credit
- 2022 Midterms: How a Democratic or GOP Congress May Impact Your Federal Taxes
- ‘The Price of Business’: Discussing State Taxation of Student Loan Forgiveness
- More Concerns with the Massachusetts Millionaire’s Tax
- Revisiting the Tax Treatment of Pass-Through Businesses: A Panel Discussion
- President Biden’s Student Loan Forgiveness: The Impact on Individuals’ State Taxes
- President Biden’s Student Loan Forgiveness: The Impact on State Tax Revenues
- Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition
- New PCMA Podcast Highlights Importance of Prescription Drug Rebates
